Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Acetate Tablets (I) vs Zytiga in mCRPC
CTR20210042Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), prostate cancer (PCa), sponsored by Hengrui Therapeutics. Started Jan 2021; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20210042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210042.